Guangdong Sunho

Sunho Biopharmaceutical is a clinical-stage biopharmaceutical company headquartered in Nanjing, China, specializing in the development of innovative biologics for oncology and autoimmune diseases. The company is a pioneer in the field of antibody-cytokine fusion proteins, utilizing its proprietary AIC™ (Antibody-Integrated Cytokine) platform to design therapies that combine the targeting precision of antibodies with the immune-modulating power of cytokines. Its lead clinical candidates, IAP0971 and IAE0972, are currently undergoing Phase II trials for various solid tumors, including non-small cell lung cancer and colorectal cancer. Sunho Biopharmaceutical's pipeline also includes ADCC-enhanced monoclonal antibodies and other multi-functional fusion proteins. The company achieved a significant milestone by listing on the Hong Kong Stock Exchange in May 2024 under the stock code 2898.HK.